NewAmsterdam Pharma (NASDAQ:NAMS) Holdings Increased by Millennium Management LLC

Millennium Management LLC lifted its holdings in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 2,850.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 494,230 shares of the company's stock after acquiring an additional 477,481 shares during the period. Millennium Management LLC owned approximately 0.53% of NewAmsterdam Pharma worth $12,702,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in NAMS. Barclays PLC increased its position in shares of NewAmsterdam Pharma by 1,813.4% in the third quarter. Barclays PLC now owns 7,596 shares of the company's stock worth $126,000 after acquiring an additional 7,199 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of NewAmsterdam Pharma by 176.9% in the third quarter. JPMorgan Chase & Co. now owns 22,351 shares of the company's stock worth $371,000 after acquiring an additional 14,280 shares in the last quarter. HB Wealth Management LLC acquired a new stake in NewAmsterdam Pharma during the 4th quarter valued at $224,000. China Universal Asset Management Co. Ltd. acquired a new stake in NewAmsterdam Pharma during the 4th quarter valued at $503,000. Finally, Jennison Associates LLC grew its holdings in NewAmsterdam Pharma by 291.9% during the 4th quarter. Jennison Associates LLC now owns 3,998,541 shares of the company's stock valued at $102,763,000 after purchasing an additional 2,978,263 shares in the last quarter. Institutional investors and hedge funds own 89.89% of the company's stock.

Insider Transactions at NewAmsterdam Pharma

In other news, Director James N. Topper acquired 1,135 shares of the business's stock in a transaction that occurred on Wednesday, March 26th. The shares were purchased at an average cost of $22.49 per share, for a total transaction of $25,526.15. Following the transaction, the director now directly owns 3,013,569 shares in the company, valued at $67,775,166.81. This trade represents a 0.04% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Louise Frederika Kooij sold 150,000 shares of NewAmsterdam Pharma stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total transaction of $3,055,500.00. Following the completion of the sale, the chief accounting officer now owns 15,000 shares in the company, valued at approximately $305,550. This represents a 90.91% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 20.84% of the company's stock.

Analyst Ratings Changes

NAMS has been the subject of a number of recent analyst reports. Scotiabank raised their price target on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a "sector outperform" rating in a report on Thursday, February 27th. UBS Group set a $41.00 price target on shares of NewAmsterdam Pharma in a report on Monday, March 3rd. Needham & Company LLC lowered their price target on shares of NewAmsterdam Pharma from $42.00 to $40.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Finally, Wall Street Zen lowered shares of NewAmsterdam Pharma from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $43.00.

NewAmsterdam Pharma Trading Up 1.4%

NAMS stock traded up $0.24 during mid-day trading on Thursday, hitting $17.55. 77,561 shares of the company were exchanged, compared to its average volume of 638,779. The company has a market capitalization of $1.93 billion, a PE ratio of -9.34 and a beta of 0.01. NewAmsterdam Pharma has a twelve month low of $14.06 and a twelve month high of $27.29. The firm has a fifty day simple moving average of $18.19 and a 200 day simple moving average of $21.12.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.04). The firm had revenue of $2.98 million for the quarter, compared to the consensus estimate of $1.46 million. As a group, sell-side analysts anticipate that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.